| Identification | Back Directory | [Name]
Uridine, 4-oxime, 5'-(2-methylpropanoate), (4Z)- | [CAS]
2492423-29-5 | [Synonyms]
Uridine, 4-oxime, 5'-(2-methylpropanoate), (4Z)- | [Molecular Formula]
C13H19N3O7 | [MDL Number]
MFCD32663515 | [MOL File]
2492423-29-5.mol | [Molecular Weight]
329.31 |
| Chemical Properties | Back Directory | [density ]
1.62±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 100 mg/mL (303.67 mM; Need ultrasonic) | [form ]
Solid | [pka]
6.71±0.20(Predicted) | [color ]
White to off-white | [InChI]
InChI=1S/C13H19N3O7/c1-6(2)12(19)22-5-7-9(17)10(18)11(23-7)16-4-3-8(15-21)14-13(16)20/h3-4,6-7,9-11,17-18,21H,5H2,1-2H3,(H,14,15,20)/t7-,9-,10-,11-/m1/s1 | [InChIKey]
HTNPEHXGEKVIHG-QCNRFFRDSA-N | [SMILES]
C(OC(=O)C(C)C)[C@H]1O[C@@H](N2C=C/C(=N/O)/NC2=O)[C@H](O)[C@@H]1O |
| Hazard Information | Back Directory | [Description]
Prodrug of antiviral nucleoside analog; inhibits SARS-CoV, SARS-CoV-2 and MERS-CoV infection. | [Definition]
ChEBI: Molnupiravir is a nucleoside analogue that is N(4)-hydroxycytidine in which the 5'-hydroxy group is replaced by a (2-methylpropanoyl)oxy group. It is the prodrug of the active antiviral ribonucleoside analog N(4)-hydroxycytidine (EIDD-1931), has activity against a number of RNA viruses including SARS-CoV-2, MERS-CoV, and seasonal and pandemic influenza viruses. It is currently in phase III trials for the treatment of patients with COVID-19. It has a role as a prodrug, an anticoronaviral agent and an antiviral drug. It is a nucleoside analogue, an isopropyl ester and a ketoxime. It is functionally related to a N(4)-hydroxycytidine. | [Biological Activity]
Molnupiravir is a broad-spectrum antiviral prodrug of the nucleoside analog β-D-N4-hydroxycytidine (NHC). It competes predominantly with CTP for incorporation; it induces lethal viral mutagenesis by increasing G to A and C to U transition mutations without inhibition of RNA synthesis in replicating coronaviruses, which prevents the development of viral resistance. In primary airway epithelial cell cultures, Molnupiravir dose-dependently inhibits SARS-CoV-2 infectious virus production; it also inhibits MERS-CoV and SARS-CoV with EC50 values in the submicromolar range. In mice infected with SARS-CoV or MERS-CoV, it improves pulmonary function, and reduces virus titer and body weight loss. Molnupiravir also displays in vivo efficacy against seasonal and pandemic influenza A shed virus. It is orally bioavailable. | [storage]
Store at -20°C |
|
|